It's not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ: BLCM)and Alnylam Pharmaceuticals (NASDAQ: ALNY)are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum's market cap is less than $350 million while Alnylam's market cap is close to $10 billion.
Better Buy: Bellicum Pharmaceuticals, Inc. vs. Alnylam Pharmaceuticals, Inc.
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться